Literature DB >> 28100358

[Study on the effect and predictive to bronchiectasis combined with rheumatoid arthritis].

W Ding1, Y F Zhao, H W Lu, S Liang, K B Cheng, J F Xu.   

Abstract

Objective: To explore the clinical characteristics of bronchiectasis(BR)coexisting in patients with rheumatoid arthritis (RA).
Methods: One hundred and forty-eight bronchiectasis patients were retrospectively analyzed. These cases were all diagnosed in the Respiratory Department of Shanghai Pulmonary Hospital and Shanghai Gongli Hospital of Pudong New Area during Jan. 2012 to Dec.2015.The patients consisted of 74 males and 74 females, aging from 45 to 79 [mean(65±11)] years. In these patients, coexisting rheumatoid arthritis was found in 34 males and 36 females, aging from 45 to 79[mean(68±12)] years(RA-BR group). Patients with bronchiectasis alone consisted of 40 males and 38 females, aging from 49 to 76 [mean(63±10)] years (BR alone group). Data between the 2 groups of patients were compared, including general clinical features, serum anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), chest high-resolution CT (HRCT), and lung function . FACED scores were used to assess the severity of bronchiectasis. Meanwhile, we analyzed the correlation between anti-CCP and FACED scores in the 2 groups.
Results: We observed an increase of serum anti-CCP in RA-BR patients compared with BR alone patients (196±68 versus 64±26, P<0.05). In addition, FACED scores in RA-BR patients were higher than those in BR patients (5.2±1.8 versus 3.1±1.4 , P< 0.05). Positive correlations between serum anti-CCP levels and FACED scores (r=0.678, r=0.461, P<0.05) in both RA-BR and BR alone groups were observed in this study. Conclusions: The disease severity scores of RA-BR patients were higher than those of patients with BR alone. Levels of serum anti-CCP may act as a predictor for the diagnosis and prognosis of bronchiectasis in patients with RA.

Entities:  

Keywords:  Arthritis, rheumatoid; Bronchiectasis

Mesh:

Substances:

Year:  2017        PMID: 28100358     DOI: 10.3760/cma.j.issn.1001-0939.2017.01.006

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  1 in total

1.  Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines.

Authors:  Ning Wang; Jie-Ming Qu; Jin-Fu Xu
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.